Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NYSE:OGN NASDAQ:SLS NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.18+0.0%$25.31$19.05▼$32.56$3.81B0.721.56 million shs1.26 million shsOGNOrganon & Co.$13.31-0.1%$8.00$5.69▼$13.44$3.49B1.578.16 million shs1.19 million shsSLSSELLAS Life Sciences Group$4.91-0.5%$4.93$1.36▼$6.14$906.97M2.247.25 million shs633,465 shsVKTXViking Therapeutics$31.26-1.0%$33.55$22.96▼$43.15$3.64B0.722.80 million shs380,653 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+2.13%+10.81%+24.73%+27.54%+32.86%OGNOrganon & Co.-0.45%+0.60%+118.13%+62.55%+52.62%SLSSELLAS Life Sciences Group-4.27%-0.40%+9.31%+32.17%+188.30%VKTXViking Therapeutics-2.17%+1.28%-6.29%+11.04%+14.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.18+0.0%$25.31$19.05▼$32.56$3.81B0.721.56 million shs1.26 million shsOGNOrganon & Co.$13.31-0.1%$8.00$5.69▼$13.44$3.49B1.578.16 million shs1.19 million shsSLSSELLAS Life Sciences Group$4.91-0.5%$4.93$1.36▼$6.14$906.97M2.247.25 million shs633,465 shsVKTXViking Therapeutics$31.26-1.0%$33.55$22.96▼$43.15$3.64B0.722.80 million shs380,653 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+2.13%+10.81%+24.73%+27.54%+32.86%OGNOrganon & Co.-0.45%+0.60%+118.13%+62.55%+52.62%SLSSELLAS Life Sciences Group-4.27%-0.40%+9.31%+32.17%+188.30%VKTXViking Therapeutics-2.17%+1.28%-6.29%+11.04%+14.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.14Buy$33.336.94% UpsideOGNOrganon & Co. 1.57Reduce$11.40-14.57% DownsideSLSSELLAS Life Sciences Group 2.00Hold$10.00102.84% UpsideVKTXViking Therapeutics 2.85Moderate Buy$95.50202.41% UpsideCurrent Analyst Ratings BreakdownLatest SLS, CPRX, OGN, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026CPRXCatalyst Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/7/2026CPRXCatalyst Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$32.005/7/2026CPRXCatalyst Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight5/1/2026VKTXViking Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.004/30/2026VKTXViking Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$95.004/30/2026VKTXViking Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$105.00 ➝ $100.004/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.004/28/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2026OGNOrganon & Co. Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$5.00 ➝ $14.004/27/2026VKTXViking Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$588.99M6.47$2.99 per share10.44$7.76 per share4.02OGNOrganon & Co.$6.22B0.56$5.75 per share2.32$3.44 per share3.88SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$4.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$214.33M$1.6918.4410.120.9936.39%36.47%31.85%5/11/2026 (Estimated)OGNOrganon & Co.$187M$0.9314.353.881.243.99%99.95%6.22%N/ASLSSELLAS Life Sciences Group-$26.86M-$0.25N/AN/AN/AN/A-63.06%-54.50%5/12/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%N/ALatest SLS, CPRX, OGN, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06N/AN/AN/AN/AN/A5/11/2026Q1 2026CPRXCatalyst Pharmaceuticals$0.64N/AN/AN/A$148.18 millionN/A4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion4/29/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/A3/19/2026Q4 2025SLSSELLAS Life Sciences Group-$0.0633-$0.05+$0.0133-$0.05N/AN/A2/12/2026Q4 2025OGNOrganon & Co.$0.73$0.63-$0.10-$0.79$1.52 billion$1.51 billion2/11/2026Q4 2025VKTXViking Therapeutics-$0.89-$1.38-$0.49-$1.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.60%N/A8.60%N/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ALatest SLS, CPRX, OGN, and VKTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/20262/12/2026OGNOrganon & Co.quarterly$0.021.01%2/23/20262/23/20263/12/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.085.82OGNOrganon & Co.9.471.971.23SLSSELLAS Life Sciences GroupN/A10.7210.72VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%OGNOrganon & Co.77.43%SLSSELLAS Life Sciences Group17.38%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%OGNOrganon & Co.1.62%SLSSELLAS Life Sciences Group1.40%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.35 million109.62 millionOptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionableSLSSELLAS Life Sciences Group10184.53 million181.95 millionNot OptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableSLS, CPRX, OGN, and VKTX HeadlinesRecent News About These CompaniesVKTX stock slips overnight: Investors pin hopes on fresh weight-loss data as Pfizer joins Eli Lilly, Novo in GLP-1 warMay 6 at 8:24 PM | msn.comViking Therapeutics: Market Betting On Big Upside Through 2030May 5 at 12:00 PM | seekingalpha.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5 at 8:41 AM | finance.yahoo.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5 at 7:05 AM | prnewswire.comHere's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 MonthsMay 4, 2026 | fool.comViking Therapeutics (NASDAQ:VKTX) Trading 7.4% Higher - Still a Buy?May 4, 2026 | marketbeat.comViking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at BTIG ResearchMay 4, 2026 | marketbeat.comHC Wainwright Brokers Decrease Earnings Estimates for VKTXMay 4, 2026 | americanbankingnews.comHC Wainwright Has Pessimistic Outlook of VKTX Q2 EarningsMay 4, 2026 | marketbeat.comWhy Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And LossMay 2, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Regeneron (REGN)May 1, 2026 | theglobeandmail.comPiper Sandler Sticks to Their Buy Rating for Viking Therapeutics (VKTX)May 1, 2026 | theglobeandmail.comViking Therapeutics faces timeline risk, but upside could be hugeMay 1, 2026 | msn.comViking Therapeutics Faces Timeline Risk—But Upside Could Be Huge...May 1, 2026 | marketbeat.comViking Therapeutics, Inc. $VKTX Shares Sold by Pictet Asset Management Holding SAMay 1, 2026 | marketbeat.comVKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal testsApril 30, 2026 | msn.comVKTX Q1 Earnings Miss on Higher Phase 3 Development CostsApril 30, 2026 | finance.yahoo.comVKTX Q1 Earnings Miss on Higher Phase 3 Development CostsApril 30, 2026 | zacks.comViking Therapeutics Earnings: Q3 Maintenance Study Data A Potential WildcardApril 30, 2026 | seekingalpha.comViking Therapeutics Inc (VKTX) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid ...April 30, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026Viking Therapeutics Faces Timeline Risk—But Upside Could Be HugeBy Chris Markoch | May 1, 2026SLS, CPRX, OGN, and VKTX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$31.18 +0.01 (+0.02%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Organon & Co. NYSE:OGN$13.30 -0.02 (-0.11%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.SELLAS Life Sciences Group NASDAQ:SLS$4.90 -0.03 (-0.51%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Viking Therapeutics NASDAQ:VKTX$31.26 -0.32 (-1.02%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
